Gabather AB Logo

Gabather AB

Developing novel GABAA receptor drugs for neuropsychiatric disorders.

GABA | ST

Overview

Corporate Details

ISIN(s):
SE0010869552 (+1 more)
LEI:
549300VLUOMD0TE1O093
Country:
Sweden
Address:
FORSKARGATAN 20 J, 151 36 Södertälje
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Gabather AB is a clinical-stage pharmaceutical company, founded in 2014, that develops novel therapeutics for neuropsychiatric disorders. The company's approach focuses on proprietary drug candidates that modulate the GABAA receptor system to restore balance in the brain and enhance cognitive function. Its primary focus areas include anti-psychotics, anti-depressants, anxiolytics, analgesics, and cognition-enhancing treatments for conditions such as Alzheimer's disease. Gabather's lead drug candidate, GT-002, has completed Phase I clinical trials, showing excellent pharmacokinetics and a strong safety profile. The company's development projects are based on over a decade of research from Lund University and the Research Institute of Biological Psychiatry in Roskilde.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Gabather AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Gabather AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.